| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
4,540,000 |
| Market
Cap: |
17.12(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.15 - $6.931 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aileron Therapeutics is a clinical stage chemoprotection oncology company. ALRN-6924, Co.'s MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is a chemoprotective agent in clinical development to employ a biomarker strategy, in which Co. focuses on treating patients with p53-mutated cancers. Co.'s clinical development program for ALRN-6924 as a selective chemoprotective agent includes: Its completed Phase 1b open-label clinical trial evaluating ALRN-6924 as a chemoprotective agent in patients with p53-mutated small cell lung cancer, undergoing treatment with second-line topotecan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
5,301 |
5,301 |
5,301 |
| Total Buy Value |
$0 |
$10,745 |
$10,745 |
$10,745 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
2 |
2 |
2 |
| Total Shares Sold |
51,466 |
51,466 |
51,466 |
51,466 |
| Total Sell Value |
$224,576 |
$224,576 |
$224,576 |
$224,576 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
4 |
4 |
4 |
4 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Satter Muneer A |
10% Owner |
– – • |
2019-04-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,909,449 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-04-01 |
4 |
S |
$1.90 |
$39,159 |
D/D |
(20,610) |
2,079,394 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-03-29 |
4 |
S |
$1.85 |
$197,099 |
D/D |
(106,540) |
2,100,004 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-03-15 |
4 |
S |
$1.92 |
$84,096 |
D/D |
(43,800) |
2,206,544 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-03-14 |
4 |
S |
$1.88 |
$25,944 |
D/D |
(13,800) |
2,250,344 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-03-13 |
4 |
S |
$2.12 |
$281,405 |
D/D |
(132,738) |
2,264,144 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-08-20 |
4 |
S |
$2.30 |
$46,892 |
D/D |
(20,388) |
2,396,882 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-08-17 |
4 |
S |
$2.10 |
$18,270 |
D/D |
(8,700) |
2,417,270 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-08-16 |
4 |
S |
$2.10 |
$18,497 |
D/D |
(8,808) |
2,425,970 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-08-15 |
4 |
S |
$2.15 |
$5,665 |
D/D |
(2,635) |
2,434,778 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-08-14 |
4 |
S |
$2.26 |
$7,458 |
D/D |
(3,300) |
2,437,413 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-08-13 |
4 |
S |
$2.36 |
$3,776 |
D/D |
(1,600) |
2,440,713 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-08-10 |
4 |
S |
$2.44 |
$13,701 |
D/D |
(5,615) |
2,442,313 |
|
- |
|
| Longenecker John P Phd |
President and CEO |
• – – |
2018-08-10 |
4 |
B |
$2.45 |
$24,500 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-08-09 |
4 |
S |
$2.48 |
$583 |
D/D |
(235) |
2,447,928 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-08-08 |
4 |
S |
$2.78 |
$2,780 |
D/D |
(1,000) |
2,448,163 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-08-07 |
4 |
S |
$2.97 |
$5,165 |
D/D |
(1,739) |
2,449,163 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-08-06 |
4 |
S |
$3.02 |
$8,885 |
D/D |
(2,942) |
2,450,902 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-08-02 |
4 |
S |
$3.33 |
$15,658 |
D/D |
(4,702) |
2,453,844 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-08-01 |
4 |
S |
$3.22 |
$26,343 |
D/D |
(8,181) |
2,458,546 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-07-31 |
4 |
S |
$3.07 |
$13,815 |
D/D |
(4,500) |
2,466,727 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-07-30 |
4 |
S |
$3.27 |
$6,540 |
D/D |
(2,000) |
2,471,227 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-07-27 |
4 |
S |
$3.38 |
$21,828 |
D/D |
(6,458) |
2,473,227 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-07-26 |
4 |
S |
$3.63 |
$28,811 |
D/D |
(7,937) |
2,479,685 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-07-25 |
4 |
S |
$3.84 |
$47,846 |
D/D |
(12,460) |
2,487,622 |
|
- |
|
105 Records found
|
|
Page 2 of 5 |
|
|
0.08 (2.08%) 
